CLL Treatment Considerations: COVID-19 and Beyond
This webinar is open to the public. You do not need to be an ACCC member to view this webinar, but you will need to create an account in order to register.
If You DO NOT Have an ACCC Account:
- To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
- ACCC and State Society Members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page.
- Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page.
- Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link.
- The green box in the upper right corner of this page will indicate “You are registered!” for this course!
If You Have an ACCC Account:
- Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button.
- You will be automatically redirected back to webinar page, and the green box in the upper right corner will say that “You are registered!” for this course!
PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!
For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar.
Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this webinar. For assistance with registration or if you do not receive an email, please contact email@example.com.
The pandemic has deeply affected the treatment patterns for patients with chronic lymphocytic leukemia (CLL). Join Dr. Javier Munoz for a discussion on considerations for treating patients with CLL during the pandemic--including best options and timing for treatment and any changes to the usual treatment regimen. Dr. Munoz will also explore what care may look like for patients with CLL beyond the pandemic and how to prepare for the future of care.
Speaker: Javier Munoz, MD, MS, FACP, Senior Associate Consultant, Division of Hematology and Medical Oncology, Mayo Clinic (Arizona)
Moderator: Christopher D'Andrea, PA-C, Physician Assistant, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Taussig Cancer Center
This webinar is part of the Returning to Practice in the Post COVID-19 Era: Resources for Treating Chronic Lymphocytic Leukemia education project. Funding & support provided by AbbVie.
Chris D'Andrea, PA-C (Moderator)
Physician Assistant, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Taussig Cancer Center
Christopher D'Andrea, PA-C, is a physician assistant in hematology oncology at Cleveland Clinic Taussig Cancer Center. Primarily managing clinic patients within the lymphoma department, he also provides care on the lymphoma/multiple myeloma and leukemia inpatient services. Additionally, Mr. D’Andrea helps staff the cancer associated thrombosis clinic, and perform and teach bone marrow biopsies. He has presented at conferences on lymphoma including chronic lymphocytic leukemia, as well as participated in local advisory board meetings.
Mr. D’Andrea earned his bachelor’s degree from Ohio State University in psychology and subsequently worked as a behavioral therapist for many years before pursuing a career as a physician assistant. He has been a physician assistant at Cleveland Clinic with the lymphoma team since completing his master’s degree in physician assistant studies at DeSales University in 2014.
Javier Munoz, MD, MS, FACP
Senior Associate Consultant, Division of Hematology and Medical Oncology, Mayo Clinic Arizona
Javier Munoz, MD, MS, FACP, specializes in treating lymphomas, and he is the director of the Lymphoma Program at Mayo Clinic in Arizona. He is triple-board-certified in internal medicine, hematology, and medical oncology. Dr. Munoz studied medicine at the Universidad Peruana Cayetano Heredia in Lima, Peru. Subsequently, he completed his residency and fellowship in hematology-oncology at Henry Ford Hospital in Michigan. Dr. Munoz also earned a master’s degree in patient-based research and had an investigational cancer therapeutics fellowship at the University of Texas MD Anderson Cancer Center in Houston before he relocated to Arizona to spearhead the development of chimeric antigen receptors (CAR) T cells. He has been the principal investigator in multiple cutting-edge lymphoma trials, including immunotherapy and CAR T-cells. Dr. Munoz has published in major medical journals, including the New England Journal of Medicine, Nature Reviews, Blood, and JAMA. Dr. Munoz's personal goal is the development of non-chemotherapy agents, via novel clinical trials, to serve patients suffering from lymphoma.